Cardiovascular Effects of Oral Pharmacotherapy in Erectile Dysfunction

Current Medical Research and Opinion

Volumn 16, Issue sup1, 2000, Pages s42-s47

  Vardi, Yoram ^a   Gruenwald, Ilan ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; ARGININE; DELAQUININE; PHENTOLAMINE; QUININE DERIVATIVE; SEROTONIN AGONIST; SILDENAFIL; TRAZODONE; UNCLASSIFIED DRUG; YOHIMBINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FAINTNESS; FATIGUE; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; NAUSEA; RHINITIS; SEDATION; SIDE EFFECT; SYNCOPE; TACHYCARDIA; TREATMENT OUTCOME; VERTIGO;

ARGININE; CARDIOVASCULAR DISEASES; HUMANS; IMPOTENCE; MALE; NEUROTRANSMITTER AGENTS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0033278313     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/0300799009117039     Document Type: Article

References (11)

1. Montague K, Barbada JH, Belker AM, Levine LA, Nadig PVV, Roehrborn CG, Sharlip ID, Bennett AH (1996). Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J. Urol., 156, 2007– 2011.
2. van Zwieten PA, Chalmers JP (1994). Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc. Drugs Ther., 6, 787 – 799.
3. Zorgniotti AW (1994). Eperience with buccal phentolamine mesylate for impotence. Int. J. Impotence Res., 6, 37 – 41.
4. Kurt U, Ozkardes H, Altug U, Germianoglu C, Gurdal M, Erol D (1994). The efficacy of antiserotoninergic agents in the treatment of erectile dysfunction. J. Urol., 152, 407 – 409.
5. Lance R, Albo M, Costabile R, Streers W (1995). Oral Trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology, 46, 117 – 120.
6. Heaton J, Morales A, Adams M, Johnston B, El-Rashidy R (1995). Recovery of erectile function by the oral administration of apomorphine. Urology, 45, 200 – 205.
7. Zorgniotti AVV, Lizza EF (1994). Effect of large doses of the nitric oxide precursor, Larginine, on erectile dysfunction. Int. J. Impotence Res., 6, 33 – 36.
8. Zusman RM, Morales A, Glasser DB, Osterloh IH (1999). Overall cardiovascular profile of sildenafil citrate. Am. J. Cardiol., 83 (5A), 35C – 44C.
9. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH (1998). Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int. J. Impotence Res., 10, 69 – 73; discussion 73 – 4.
10. Kloner RA, Jarrow JP (1999). Erectile dysfunction and sildenafil citrate and cardiologists [editorial]. Am. J. Cardiol., 83, 576–582, A7.
11. Conti CR, Pepine CJ, Sweeney M (1999). Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol., Mar, 83 (5A), 29C – 34C.